Stock listing
Frankfurt:PBS0 Precision BioSciences, Inc. Aktie
German listing (Frankfurt) of Precision BioSciences, Inc. · home listing NASDAQ:DTIL
Follow Precision BioSciences, Inc. into a list and get an email when it puts out news.
Share price · FWB:PBS0
€5.76 EUR -0.24 (-4.0%)
Close on Nov 20, 2026
- Day range
- €5.76 – €6.19 EURNov 20, 2026
- Market cap
- €159.0M EURAt the close on Nov 20, 2026 · price × 27.60M shares outstanding
- 52-week range
- €2.91 – €10.05 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €897 EURMedian day 0 shares · 47 days with no trades · last 3 months, Aug 20, 2026 – Nov 12, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:DTIL · Home | $7.40 USD | +0.30 (+4.2%) | 429,792 | $6.77 | $7.55 | $6.77 | $7.10 | Close on Nov 20, 2026 |
| Frankfurt:PBS0 | €5.76 EUR | -0.24 (-4.0%) | — | €6.19 | €6.19 | €5.76 | €6.00 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 12, 2026 · FWB:PBS0 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €7.202 | -0.581 | -7.5% | €8.067 | €8.098 | €7.198 | 0 | |
| €7.783 | -0.192 | -2.4% | €8.35 | €8.374 | €7.709 | 0 | |
| €7.975 | -1.992 | -20.0% | €8.458 | €8.547 | €7.957 | 3,262 | |
| €9.967 | +2.379 | +31.4% | €9.185 | €10.05 | €7.989 | 0 | |
| €7.588 | +0.415 | +5.8% | €8.623 | €8.706 | €7.56 | 2,378 | |
| €7.173 | +1.088 | +17.9% | €7.173 | €7.173 | €7.173 | 280 | |
| €6.085 | +0.515 | +9.2% | €6.085 | €6.085 | €6.085 | 280 | |
| €5.57 | -0.124 | -2.2% | €6.051 | €6.064 | €5.556 | 0 | |
| €5.694 | -0.30 | -5.0% | €6.188 | €6.205 | €5.621 | 0 | |
| €5.994 | -0.245 | -3.9% | €6.521 | €6.548 | €5.956 | 0 | |
| €6.239 | +0.625 | +11.1% | €6.586 | €6.619 | €6.166 | 30 | |
| €5.614 | +0.415 | +8.0% | €5.984 | €5.988 | €5.595 | 30 | |
| €5.199 | -0.38 | -6.8% | €5.63 | €5.697 | €5.169 | 0 | |
| €5.579 | +0.298 | +5.6% | €5.864 | €5.882 | €5.551 | 0 | |
| €5.281 | -0.081 | -1.5% | €5.952 | €5.97 | €5.20 | 0 | |
| €5.362 | -0.183 | -3.3% | €5.826 | €5.863 | €5.353 | 0 | |
| €5.545 | +0.499 | +9.9% | €5.731 | €5.751 | €5.523 | 0 | |
| €5.046 | +0.221 | +4.6% | €5.436 | €5.438 | €5.006 | 0 | |
| €4.825 | -0.098 | -2.0% | €5.083 | €5.087 | €4.805 | 0 | |
| €4.923 | -0.04 | -0.8% | €5.448 | €5.48 | €4.895 | 0 | |
| €4.963 | -0.087 | -1.7% | €5.305 | €5.352 | €4.931 | 0 | |
| €5.05 | -0.219 | -4.2% | €5.337 | €5.347 | €5.048 | 0 | |
| €5.269 | -0.179 | -3.3% | €5.764 | €5.772 | €5.25 | 0 | |
| €5.448 | +0.277 | +5.4% | €5.913 | €5.951 | €5.392 | 0 | |
| €5.171 | +0.084 | +1.7% | €5.616 | €5.622 | €5.169 | 716 | |
| €5.087 | +0.047 | +0.9% | €5.438 | €5.444 | €5.071 | 0 | |
| €5.04 | -0.079 | -1.5% | €5.38 | €5.396 | €5.005 | 0 | |
| €5.119 | -0.042 | -0.8% | €5.522 | €5.559 | €5.112 | 0 | |
| €5.161 | -0.038 | -0.7% | €5.499 | €5.538 | €5.157 | 0 | |
| €5.199 | +0.136 | +2.7% | €5.559 | €5.614 | €5.195 | 360 | |
| €5.063 | +0.076 | +1.5% | €5.421 | €5.453 | €5.059 | 0 | |
| €4.987 | -0.097 | -1.9% | €5.338 | €5.433 | €4.974 | 0 | |
| €5.084 | +0.219 | +4.5% | €5.431 | €5.455 | €5.051 | 0 | |
| €4.865 | -0.638 | -11.6% | €5.354 | €5.357 | €4.857 | 0 | |
| €5.503 | +0.048 | +0.9% | €5.503 | €5.503 | €5.503 | 4 | |
| €5.455 | -0.78 | -12.5% | €5.455 | €5.455 | €5.455 | 0 | |
| €6.235 | +0.662 | +11.9% | €6.235 | €6.235 | €6.235 | 0 | |
| €5.573 | -0.191 | -3.3% | €5.573 | €5.573 | €5.573 | 16 | |
| €5.764 | +0.357 | +6.6% | €5.764 | €5.764 | €5.764 | 16 | |
| €5.407 | +0.06 | +1.1% | €5.694 | €5.753 | €5.317 | 0 | |
| €5.347 | +0.085 | +1.6% | €5.695 | €5.705 | €5.294 | 0 | |
| €5.262 | -0.199 | -3.6% | €5.605 | €5.657 | €5.255 | 0 | |
| €5.461 | -0.285 | -5.0% | €5.785 | €5.824 | €5.432 | 0 | |
| €5.746 | +0.032 | +0.6% | €6.085 | €6.107 | €5.702 | 0 | |
| €5.714 | +0.13 | +2.3% | €6.112 | €6.185 | €5.706 | 86 | |
| €5.584 | -0.20 | -3.5% | €6.131 | €6.161 | €5.568 | 0 | |
| €5.784 | +0.027 | +0.5% | €6.23 | €6.308 | €5.753 | 0 | |
| €5.757 | -0.527 | -8.4% | €6.251 | €6.29 | €5.688 | 0 | |
| €6.284 | +0.324 | +5.4% | €6.284 | €6.284 | €6.284 | 0 | |
| €5.96 | +0.017 | +0.3% | €6.188 | €6.189 | €5.928 | 0 | |
| €5.943 | -0.08 | -1.3% | €6.301 | €6.351 | €5.923 | 0 | |
| €6.023 | +0.069 | +1.2% | €6.483 | €6.529 | €6.022 | 0 | |
| €5.954 | -0.131 | -2.2% | €6.438 | €6.457 | €5.942 | 0 | |
| €6.085 | -0.30 | -4.7% | €6.567 | €6.648 | €6.085 | 0 | |
| €6.385 | -0.215 | -3.3% | €7.102 | €7.124 | €6.382 | 2 | |
| €6.60 | -0.06 | -0.9% | €7.119 | €7.119 | €6.528 | 0 | |
| €6.66 | -0.003 | 0.0% | €7.269 | €7.285 | €6.635 | 0 | |
| €6.663 | -0.13 | -1.9% | €7.081 | €7.083 | €6.637 | 0 | |
| €6.793 | -0.108 | -1.6% | €7.447 | €7.482 | €6.769 | 0 | |
| €6.901 | -0.213 | -3.0% | €7.287 | €7.37 | €6.846 | 44 | |
| €7.114 | +0.526 | +8.0% | €7.114 | €7.114 | €7.114 | 0 |
Splits
1 split · FWB:PBS0 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-30 | Consolidation |
- Ticker
- Frankfurt:PBS0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 20, 2026
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Latest deck · Nov 5, 2026
AASLD 2026
Conference · 74 slides
Latest news
Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Nov 5, 2026
Closed €7.17 (+17.9%) on Nov 5, 2026
Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study
Nov 5, 2026
Closed €7.17 (+17.9%) on Nov 5, 2026
Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure
Nov 5, 2026
Closed €7.17 (+17.9%) on Nov 5, 2026
Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 3, 2026
Closed €5.57 (-2.2%) on Nov 3, 2026
Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026
Oct 29, 2026
Closed €6.24 (+11.1%) on Oct 29, 2026
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
Oct 8, 2026
Closed €5.09 (+0.9%) on Oct 8, 2026
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Aug 24, 2026
Closed €6.79 (-1.6%) on Aug 24, 2026
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 6, 2026
Closed €6.02 (+1.3%) on Aug 6, 2026
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
Jul 31, 2026
Closed €5.56 (-0.1%) on Jul 31, 2026
Precision BioSciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 31 in the last 12 months · 199 in all · newest Nov 20, 2026 · oldest 2019
- Decks
- 54 decks · latest Nov 5, 2026
Where Precision BioSciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:DTIL · Home listing | NASDAQ | United States | USD |
| gettex:PBS0 | gettex | Germany | EUR |
| LS Exchange:A400AS | LS Exchange | Germany | EUR |
| Lang & Schwarz:A400AS | Lang & Schwarz | Germany | EUR |
| Stuttgart:PBS0 | Stuttgart | Germany | EUR |
| BOATS:DTIL | BOATS | United States | USD |
| Frankfurt:PBS0 · This page | Frankfurt | Germany | EUR |
| Dusseldorf:PBS0 | Dusseldorf | Germany | EUR |
| Hamburg:PBS0 | Hamburg | Germany | EUR |
| Munich:PBS0 | Munich | Germany | EUR |
| Tradegate:PBS0 | Tradegate | Germany | EUR |
Valuation
EV/sales 5.1× against a median of 467×: the lowest of 2 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $228.3M USD
- P/E
- Loss
- EV/sales
- 5.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 5.5×
- Gross margin
- Not reported
- Operating margin
- −80.3%
- Net margin
- −85.6%
- Debt to equity
- 0.5×
- Beta vs S&P 500
- 0.30
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Precision BioSciences, Inc. · NASDAQ:DTIL | US$282.5M | US$228.3M | n/a | 5.1× | n/a | 5.5× | −85.6% | 0.5× | 0.30 |
| Contineum Therapeutics, Inc. · NASDAQ:CTNM | US$286.1M | US$47.86M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.53 |
| TRex Bio, Inc. · NASDAQ:TRXB | US$283.1M | US$205.0M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Greenwich LifeSciences, Inc. · NASDAQ:GLSI | US$282.6M | US$276.7M | n/a | n/a | n/a | n/a | n/a | n/a | 2.80 |
| AP Biosciences, Inc. · TPEX:6945 | US$282.3M | US$215.7M | n/a | n/a | n/a | 4.0× | n/a | 0.0× | n/a |
| Fulcrum Therapeutics, Inc. · NASDAQ:FULC | US$281.8M | −US$17.87M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.42 |
| Circio Holding ASA · OSL:CRNA | US$281.0M | US$225.8M | n/a | n/a | n/a | 5.3× | n/a | 0.0× | n/a |
| Relmada Therapeutics, Inc. · NASDAQ:RLMD | US$279.5M | US$77.42M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.57 |
| Benitec Biopharma Inc. · NASDAQ:BNTC | US$276.1M | US$99.78M | n/a | n/a | n/a | 1.6× | n/a | 0.0× | 1.46 |
| Galectin Therapeutics Inc. · NASDAQ:GALT | US$271.4M | US$293.0M | n/a | n/a | n/a | n/a | n/a | n/a | 1.20 |
| Vicore Pharma Holding AB · OMXSTO:VICO | US$271.2M | US$182.6M | n/a | 467× | n/a | 3.3× | n/a | 0.0× | n/a |
| Median of the others | US$281.4M | US$193.8M | 467× | 1.6× | 0.0× | 1.50 |
Forecasts
5 strong buy · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 29.40 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.85 · 4 analysts
- Revenue, year to Dec 2026
- 11.35M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Michael Amoroso | President, Chief Executive Officer |
| Naresh Tanna | Chief Financial Officer |
| Alex Kelly | Chief Operating Officer |
| Dario Scimeca | Chief Legal Officer |
| Neil Leatherbury | Senior Vice President of Chemistry, Manufacturing, and Controls (CMC) |
| Cassie Gorsuch | Chief Scientific Officer |
| Cindy Atwell | Chief Development Officer |
| Jeff Smith | Chief Research Officer |
| Juli Blanche | Chief People Officer |
| Mark Sulkowski | Head Clinical Development Advisor |
Board
| Director |
|---|
| Geno Germano |
| Shari Lisa Piré |
| Stanley Frankel |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 3, 2026 · Before open | +0.3% |
| Q2 2026 | Aug 6, 2026 · Before open | −0.7% |
| Q1 2026 | May 5, 2026 · Before open | −2.4% |
| Q4 2025 | Mar 12, 2026 | +12.1% |
| Q3 2025 | Nov 3, 2025 · Before open | −9.8% |
| Q2 2025 | Aug 7, 2025 · Before open | −5.0% |
| Q1 2025 | May 15, 2025 · Before open | −8.1% |
| Q4 2024 | Mar 25, 2025 · Before open | −9.8% |
| Q3 2024 | Nov 4, 2024 · Before open | −8.1% |
| Q2 2024 | Aug 1, 2024 · Before open | +0.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · Before open | +8.1% |
| Q4 2023 | Mar 27, 2024 · Before open | +1.8% |
| Q3 2023 | Nov 7, 2023 · Before open | −2.5% |
| Q2 2023 | Aug 4, 2023 · Before open | +3.9% |
| Q1 2023 | May 9, 2023 · Before open | 0.0% |
| Q4 2022 | Mar 9, 2023 · Before open | −11.3% |
| Q3 2022 | Nov 8, 2022 · Before open | +2.4% |
| Q2 2022 | Aug 8, 2022 · Before open | −7.5% |
| Q1 2022 | May 9, 2022 · Before open | −9.8% |
| Q4 2021 | Mar 15, 2022 · Before open | −16.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| AASLD 2026 | Conference | 74 slides | Nov 5, 2026 |
| Investor Presentation (November 2026) | Investor deck | 76 slides | November 2026 |
| Investor Presentation (August 2026) | Investor deck | 53 slides | August 2026 |
| Technical Presentation (May 2026) | Technical | 58 slides | May 27, 2026 |
| Corporate Update (March 2026) | Corporate update | 45 slides | Mar 17, 2026 |
| Investor Presentation (January 2026) | Investor deck | 33 slides | January 2026 |
| AASLD 2025 | Conference | 19 slides | Nov 10, 2025 |
| Corporate Update (November 2025) | Corporate update | 43 slides | November 2025 |
| Investor Presentation (September 2025) | Investor deck | 44 slides | September 2025 |
| Investor Presentation (May 2025) | Investor deck | 56 slides | May 2025 |
Show 50 decks
This page holds 50 of 54 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Announced: about US$125M · US$7.75 a share · TD Cowen +1 Dealers: TD Cowen (co-lead), Guggenheim Securities (co-lead) Buyers: First Light Asset Management; MPM BioImpact; Bleichroeder LP; Lynx1 Capital Management; Readout Capital; Aberdeen Investments; Driehaus Capital Management Use of proceeds: Continued research and development of PBGENE-HBV and PBGENE-DMD, working capital and general corporate purposes | Nov 5, 2026 |
| Strategic investment of common stock Announced: US$2.25M · US$11.17 a share Buyers: TG Therapeutics, Inc. ($2.25 million for 201,504 shares of common stock at $11.17 per share) Use of proceeds: Supports cash runway through 2028 and focus on in vivo gene editing pipeline | Mar 2, 2026 |
| Public offering of common stock, pre-funded warrants and warrants Announced: about US$75M · US$6.14 a share · ½ warrant at US$7.25 for 60 months · Guggenheim Securities Dealers: Guggenheim Securities (lead) Buyers: Aberdeen Investments; Bleichroeder LP; Driehaus Capital Management; Empery Asset Management LP; Lynx1 Capital Management; Octagon Capital; Readout Capital; Sphera Funds Management; Stonepine Capital Management Use of proceeds: Ongoing and planned research and development, working capital and general corporate purposes | Nov 10, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Mar 27, 2019.
- Price
- US$16.00 a share
- Shares offered
- 7,900,000 shares of common stock
- Offering size
- US$126.4 million
- Underwriters' option
- Up to 1,185,000 more shares
- Underwriters
- J.P. Morgan, Goldman Sachs & Co. LLC, Jefferies, Barclays · In the order on the cover
- Shares delivered
- On or about Apr 1, 2019
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Oct 19, 2018 |
| Filed publicly | Mar 1, 2019 |
| Amended twice | Newest Mar 18, 2019 |
| Shares registered with an exchange | Mar 19, 2019 |
| Declared effective by the SEC | Mar 27, 2019 |
| Final prospectus, with the price | Mar 28, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Mar 28, 2019 |
| EFFECT · Notice that a registration is effective | Mar 27, 2019 |
| CORRESP · Letter to the SEC | Mar 25, 2019 |
| CORRESP · Letter to the SEC | Mar 25, 2019 |
| CERT · Exchange's certificate of listing | Mar 25, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | Mar 19, 2019 |
| UPLOAD · Letter from the SEC | Mar 18, 2019 |
| S-1/A · Registration statement, amended | Mar 18, 2019 |
| CORRESP · Letter to the SEC | Mar 13, 2019 |
| S-1/A · Registration statement, amended | Mar 13, 2019 |
All 20 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Mar 8, 2019 |
| UPLOAD · Letter from the SEC | Mar 6, 2019 |
| S-1 · Registration statement | Mar 1, 2019 |
| UPLOAD · Letter from the SEC | Feb 22, 2019 |
| DRSLTR · Letter to the SEC with a draft | Feb 21, 2019 |
| DRS/A · Draft registration statement, amended | Feb 21, 2019 |
| DRSLTR · Letter to the SEC with a draft | Dec 28, 2018 |
| DRS/A · Draft registration statement, amended | Dec 28, 2018 |
| UPLOAD · Letter from the SEC | Nov 16, 2018 |
| DRS · Draft registration statement | Oct 19, 2018 |
Open IPO · From the cover of the final prospectus (424B4) filed Mar 28, 2019
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 34.3M | 68.7M | 48.7M | 25.1M | 115.5M | 24.3M | 1.07B | 10.9M | 6.48M | 7.01M |
| Cost of revenue | 2.75M | 4.58M | 8.26M | 9.00M | 0 | 0 | 0 | |||
| Gross profit | 34.3M | 68.7M | 48.7M | 25.1M | 115.5M | 24.3M | 22.2M | 10.9M | 6.48M | 7.01M |
| Research and development | 54.2M | 59.6M | 53.4M | 46.1M | 115.2M | 98.1M | 82.4M | 45.1M | 20.3M | 9.10M |
| Selling, general and administrative | 32.2M | 35.3M | 39.1M | 41.3M | 39.7M | 36.1M | 27.0M | 13.7M | 8.02M | 6.17M |
| Operating income | -52.1M | -26.2M | -43.7M | -62.3M | -39.4M | -109.8M | -87.2M | -47.9M | -22.0M | -8.83M |
| Depreciation and amortization | 1.47M | 3.40M | 6.82M | 7.80M | 8.98M | 8.78M | 5.32M | 2.35M | 1.44M | 640.0K |
| EBITDA | -50.7M | -22.8M | -36.9M | -54.5M | -30.4M | -101.1M | -81.9M | -45.6M | -20.5M | -8.19M |
| Interest expense | 1.42M | 1.78M | 2.23M | 1.11M | 132.0K | 822.0K | 182.0K | 0 | 0 | 0 |
| Income before tax | -45.7M | 7.17M | -42.5M | -72.9M | -30.6M | -109.0M | -92.9M | -46.0M | -21.1M | -8.26M |
| Income tax | 0 | 0 | 27.2M | 11.3M | 316.0K | 23.0K | -9.58M | 1.88M | -754.0K | -5.00K |
| Net income | -45.7M | 7.17M | -61.3M | -111.6M | -30.6M | -109.0M | -92.9M | -46.0M | -21.1M | -8.25M |
| Earnings per share, basic | -3.56 | 1.05 | -15.96 | -38.10 | -0.52 | -2.09 | -2.21 | -2.92 | -18.81 | -0.49 |
| Earnings per share, diluted | -3.56 | 1.04 | -15.96 | -38.10 | -0.52 | -2.09 | -2.21 | -2.92 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 110.8M | 85.9M | 116.7M | 189.6M | 143.7M | 89.8M | 180.9M | 103.2M | 62.8M | 93.4M |
| Short-term investments | 4.76M | 413.0K | 0 | |||||||
| Receivables | 0 | 229.0K | 901.0K | 720.0K | 488.0K | 10.0M | 965.0K | 523.0K | 22.0K | 386.0K |
| Inventory | 7.55M | 17.4M | 5.76M | 9.50M | ||||||
| Current assets | 118.7M | 95.0M | 136.4M | 199.1M | 161.8M | 105.6M | 193.7M | 115.7M | 64.3M | 94.4M |
| Property, plant and equipment | 1.43M | 3.09M | 6.34M | 11.8M | 25.2M | 35.1M | 39.6M | 21.1M | 8.14M | 3.54M |
| Total assets | 154.4M | 136.4M | 159.8M | 238.2M | 211.5M | 150.2M | 235.2M | 138.6M | 72.7M | 98.4M |
| Accounts payable | 296.0K | 1.31M | 2.97M | 653.0K | 1.14M | 792.0K | 2.04M | 2.22M | 1.81M | 1.29M |
| Current liabilities | 8.91M | 15.0M | 50.0M | 59.7M | 36.0M | 42.8M | 26.9M | 14.1M | 9.20M | 8.34M |
| Long-term debt | 22.4M | 22.3M | 22.2M | 2.48M | ||||||
| Total debt | 28.8M | 30.0M | 31.3M | 22.2M | 2.48M | 10.5M | ||||
| Total liabilities | 62.2M | 80.0M | 140.9M | 177.7M | 120.3M | 105.7M | 96.9M | 98.6M | 99.1M | 103.2M |
| Shareholders' equity | 92.2M | 56.4M | 18.9M | 60.4M | 91.2M | 44.4M | 138.3M | 40.0M | -26.4M | -4.75M |
| Shares outstanding | 24.1M | 8.20M | 4.16M | 3.70M | 60.9M | 52.7M | 51.2M | 15.9M | 1.12M | 16.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -65.8M | -58.4M | -84.1M | -45.8M | -10.9M | -87.4M | -71.0M | -51.7M | -24.2M | 92.3M |
| Capital spending | -85.0K | -250.0K | -1.96M | -3.32M | -5.05M | -5.03M | -24.7M | -14.3M | -5.57M | -2.08M |
| Free cash flow | -65.9M | -58.7M | -86.1M | -49.1M | -15.9M | -92.4M | -95.7M | -66.0M | -29.7M | 90.2M |
| Cash from investing | -634.0K | -215.0K | 5.83M | -3.32M | -5.80M | -5.03M | -24.7M | -15.7M | -5.51M | -2.08M |
| Cash from financing | 95.2M | 50.5M | 5.39M | 95.0M | 70.5M | 1.33M | 173.4M | 107.8M | -937.0K | -12.4M |
| Dividends paid | -12.4M | |||||||||
| Share buybacks | 74.7M | 67.3M | 689.0K | 136.4M | 0 | -952.0K | 49.0K | |||
| Change in cash | 28.7M | -8.21M | -72.9M | 45.9M | 53.9M | -91.1M | 77.7M | 40.4M | -30.6M | 77.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 10, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 9, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Nov 6, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 6, 2026 | Current report | SEC |
| 424B5 · Prospectus | Nov 5, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | Nov 5, 2026 | Other filings | SEC |
| FWP · Free writing prospectus | Nov 5, 2026 | Offer document | SEC |
| 8-K · Current report | Nov 5, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 3, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 3, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 3, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 24, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 24, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Aug 7, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 3 · Initial statement of ownership | Aug 3, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 3, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 27, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 20, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 1, 2026 | Current report | SEC |
| 8-K · Current report | Jun 16, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 8-K · Current report | May 27, 2026 | Current report | SEC |
| 8-K · Current report | May 26, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 15, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 8, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 8, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 8, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Mar 27, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 17, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 11, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 10, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 22, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 22, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jan 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 21, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 13, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | Jan 8, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 5, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 2, 2026 | Other filings | SEC |
| S-3 · Registration statement | Dec 30, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Dec 30, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2025 | Current report | SEC |
| 424B5 · Prospectus | Nov 12, 2025 | Offer document | SEC |
| FWP · Free writing prospectus | Nov 10, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 3, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 3, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2025 | Results | SEC |
| 4 · Change in ownership | Sep 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 2, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 6, 2025 | Current report | SEC |
| 4 · Change in ownership | Jul 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 25, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 15, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 15, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 15, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 4, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 26, 2025 | Big-stake notice | SEC |
| 424B5 · Prospectus | Mar 26, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 26, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 25, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 24, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 18, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Mar 7, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 5, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 29, 2025 | Management or board change | SEC |
| 144 · Notice of proposed sale | Jan 24, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 21, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 8, 2025 | Results | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 4, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 4, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 4, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2024 | Results | SEC |
| 8-K · Current report | Oct 24, 2024 | Results | SEC |
| 8-K · Current report | Sep 12, 2024 | Management or board change | SEC |
| 8-K · Current report | Sep 3, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 1, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 1, 2024 | Results | SEC |
| S-8 · Registration statement for employee plans | Jul 1, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 10, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 10, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 10, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
This page holds 200 of 611 filings. Open Filings
Cap table
Built by 6ix from Precision BioSciences, Inc.’s releases · as of Nov 16, 2026
- Common shares
- 38,170,796
- Fully diluted
- 38,249,088
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 38,170,796 | |
| Options and RSUs | 78,292 | Nov 16, 2026 |
Warrants and options
| Lot |
|---|
| RSUs · expiry not stated |
| RSUs · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 38,170,796 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Shalini Sharp Other companies: Iambic Therapeutics, Inc. (Board Member · Since at least Nov 5, 2026); BeOne Medicines Ltd. Class A (Director · Since at least Jun 11, 2026); Septerna, Inc. (Director · Since at least Oct 24, 2024); Organon & Co. (Director · Since at least May 14, 2021); Neurocrine Biosciences, Inc. (Director · Since at least Feb 1, 2020); Nuvation Bio Inc. (Director · Jun 30, 2020 – Feb 10, 2021 · Past); Sutro Biopharma, Inc. (Director · Nov 8, 2018 – Jun 6, 2022 · Past); Ultragenyx Pharmaceutical Inc. (EVP, Finance · Jan 30, 2014 – Oct 14, 2020 · Past); Agenus Inc. (Director · Oct 1, 2006 – Mar 2, 2018 · Past) | Director · Mar 27, 2019 – May 10, 2021 · Past |
| Geno Germano Other companies: Harmony Biosciences Holdings, Inc. (Director · Since at least Apr 2, 2026); Entera Bio Ltd. (Chairman of the Board · Since at least Feb 4, 2026); Sage Therapeutics Inc (Director · Since at least Jun 6, 2018); Bioverativ Inc (Director · Jan 31, 2018 – Mar 8, 2018 · Past); The Medicines Company (Director · Nov 9, 2017 – Jan 6, 2020 · Past) | Director · Since at least Mar 10, 2020 |
| Robert J Adelman Other companies: Metacrine Inc (Director · Sep 15, 2020 – Sep 18, 2020 · Past); Aryx Therapeutics Inc (Director · Nov 7, 2007 – Nov 14, 2008 · Past); Volcano Corp (Director · Jun 14, 2006 – Jun 20, 2006 · Past) | Director · Mar 27, 2019 – Apr 1, 2019 · Past |
| Alan F. List Other companies: TuHURA Biosciences, Inc. (Director · Since at least Oct 18, 2024) | Chief Medical Officer · Apr 26, 2021 – May 1, 2024 · Past |
| Christopher Heery Other companies: Arcellx Inc (CHIEF MEDICAL OFFICER · Since at least Feb 3, 2022) | Chief Medical Officer · Sep 30, 2019 – Jun 8, 2020 · Past |
| John Alexander Kelly Other companies: Forest Laboratories Inc (SVP - Chief Comm's & IR · Oct 24, 2013 – Jun 30, 2014 · Past) | Chief Financial Officer · Since at least Jan 1, 2021 |
| Melinda Brown Other companies: Tapestry, Inc. (SVP, Controller and PAO · Aug 20, 2016 – Aug 17, 2018 · Past) | Director · Since at least May 26, 2022 |
| Michael Amoroso Other companies: Abeona Therapeutics Inc. (Director · Since at least Oct 26, 2020) | President, Chief Executive Officer · Since at least Oct 15, 2021 |
| Raymond F Schinazi Other companies: Cocrystal Pharma, Inc. (Director · Nov 25, 2014 – Sep 21, 2018 · Past) | Director · Mar 27, 2019 – May 10, 2022 · Past |
| Samuel C Wadsworth Other companies: Dimension Therapeutics (Chief Scientific Officer · Oct 21, 2015 – Nov 7, 2017 · Past) | Director · Nov 8, 2021 – Jun 4, 2024 · Past |
All 32 people
| Person | Seat |
|---|---|
| Shane Barton Other companies: BioAge Labs, Inc. (SVP, Finance · Since at least Sep 25, 2024) | VP & Corporate Controller · Jan 1, 2021 – Jun 7, 2023 · Past |
| Tony Dung Ling Yao Other companies: 4D Molecular Therapeutics, Inc. (Director · Dec 10, 2020 – Dec 15, 2020 · Past) | Director · Mar 27, 2019 – Apr 3, 2019 · Past |
| Abid Ansari | Chief Financial Officer · Mar 27, 2019 – Jun 15, 2020 · Past |
| Alex Kelly | Chief Operating Officer · Since at least Aug 6, 2026 |
| Cassandra Louise Gorsuch | Chief Scientific Officer · Since at least Aug 1, 2026 |
| Cassie Gorsuch | Chief Scientific Officer · Since at least Aug 6, 2026 |
| Cindy Atwell | Chief Development Officer · Since at least Jul 27, 2026 |
| Dario Scimeca | Chief Legal Officer · Since at least Jun 10, 2019 |
| David S Thomson | Chief Operating Officer · Mar 27, 2019 – Jun 23, 2021 · Past |
| Derek Jantz | Chief Scientific Officer, Director · Mar 27, 2019 – Jun 7, 2022 · Past |
| Fayaz Khazi | CEO of Elo Life Systems · Mar 27, 2019 – Jun 7, 2021 · Past |
| Jeff Smith | Chief Research Officer · Since at least Oct 8, 2026 |
| J Jefferson Smith | Chief Research Officer · Since at least Sep 1, 2022 |
| Juli Blanche | Chief People Officer · Since at least Nov 5, 2026 |
| Kevin Buehler | Director · Since at least Nov 8, 2019 |
| Mark Sulkowski | Head Clinical Development Advisor · Since at least Oct 8, 2026 |
| Matthew R Kane | President and CEO, Director · Sep 23, 2019 – Jun 7, 2021 · Past |
| Mei Zhang Lu Burris | Chielf Accounting Officer · Since at least Aug 1, 2026 |
| Naresh Tanna | Chief Financial Officer · Since at least Aug 1, 2026 |
| Neil Leatherbury | Senior Vice President of Chemistry, Manufacturing, and Controls (CMC) · Since at least Oct 8, 2026 |
| Shari Lisa Piré | Director · Since at least Nov 8, 2021 |
| Stanley Frankel | Director · Since at least Apr 12, 2021 |
Log in to ask 6ix AI your own questions about Precision BioSciences, Inc.